Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: Adverse effects do not influence compliance

Sexually Transmitted Diseases

Volumn 37, Issue 11, 2010, Pages 681-686

  Sonder, Gerard J B ^a,b   Prins, Jan M ^b   Regez, Rosa M ^c   Brinkman, Kees ^c   Mulder, Jan Willem ^d   Veenstra, Jan ^e   Claessen, Frans A P ^f   Hoek, Anneke Van Den ^a,b  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATAZANAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MYALGIA; NAUSEA; NETHERLANDS; PATIENT COMPLIANCE; PRESCRIPTION; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; URTICARIA;

ADULT; AGED; ANTI-HIV AGENTS; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; NETHERLANDS; OLIGOPEPTIDES; PATIENT COMPLIANCE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; SEXUAL BEHAVIOR; YOUNG ADULT;

EID: 78149282525     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181e2f999     Document Type: Article

References (22)

1. Cardo DM, Culver DH, Ciesielski CA, et al; Centers for Disease Control and Prevention Needlestick Surveillance Group. A casecontrol study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-1490.
2. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: Antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007;146:591-601.
3. Richens J, Edwards SG, Sadiq ST. Can the promotion of postexposure prophylaxis following sexual exposure to HIV (PEPSE) cause harm? Sex Transm Infect 2005;81:190-191.
4. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004;18:787-792.
5. Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immun Defic Syndr 2004;35:519-525.
6. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: Recommendations from the US Department of Health and Human Services. MMWR Recomm Rep 2005;54(RR-2): 1-20.
7. Almeda J, Casabona J, Simon B, et al. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Eurosurveillance 2004;9:35-40.
8. Winston A, McAllister J, Amin J, et al. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV postexposure prophylaxis. HIV Med 2005;6:191-197.
9. Sonder GJ, Regez RM, Brinkman K, et al. Prophylaxis and follow-up after possible exposure to HIV, hepatitis B virus, and hepatitis C virus outside hospital: Evaluation of policy 2000-3. BMJ 2005;330:825-829.
10. Sonder GJ, van den Hoek JA, Regez RM, et al. Trends in HIV PEP prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sex Transm Dis 2007;34:288-293.
11. Garcia MT, Figueiredo RM, Moretti ML, et al. Postexposure prophylaxis after sexual assaults: A prospective cohort study. Sex Transm Dis 2005;32:214-219.
12. Loutfy MR, Macdonald S, Myhr T, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther 2008;13:87-95.
13. Shoptaw S, Rotheram-Fuller E, Landovitz RJ, et al. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. AIDS Care 2008;20:376-381.
14. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP Study. J Infect Dis 2001;183:707-714.
15. Linden JA, Oldeg P, Mehta SD, et al. HIV Postexposure prophylaxis in sexual assault: Current practice and patient adherence to treatment recommendations in a large urban teaching hospital. Acad Emerg Med 2005;12:640-646.
16. Wiebe ER, Connor SE, McGregor M, et al. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. Can Med Assoc J 2000;162:641-645.
17. Roland ME. Postexposure prophylaxis after sexual exposure to HIV. Curr Opin Infect Dis 2007;20:39-46.
18. Hospers HJ, Dörfler TT, Zuilhof W. Monitoronderzoek Amsterdam 2004 [in Dutch]. Amsterdam, The Netherlands: Schorerstichting, 2004. ISBN 90-7334-125-6.
19. Hospers HJ, Dörfler TT, Zuilhof W. (2006). Schorer Monitor 2006. Amsterdam: Schorer. ISBN 90-7334-131-0.
20. Hospers HJ, Dörfler, TT, Zuilhof W, et al. (2007). Schorer Monitor 2007. Amsterdam: Schorer. ISBN 978-90-7334-132-9.
21. van Rijckevorsel GG, Sonder GJ, Bovée LP, et al. Trends in hepatitis A, B, and shigellosis compared with gonorrhea and syphilis in men who have sex with men in Amsterdam, 1992-2006. Sex Transm Dis 2008;35:930-934.
22. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005;41:1507-1513.